Biomea Fusion Opens Icovamenib (100 mg) Plus Semaglutide Obesity Trial
BMEA•Biomea Fusion will evaluate its menin inhibitor icovamenib (100 mg QD) plus low-dose semaglutide over 24 weeks versus semaglutide alone in overweight or obese non-diabetic participants at University of Leicester, enrolling in Q3. Primary outcome at Week 24 will assess body weight, composition and physical function.
1. Collaboration overview
Biomea Fusion has partnered with the University of Leicester’s Leicester Diabetes Centre to add an icovamenib–semaglutide arm to the OPAL adaptive platform trial, aiming to explore enhanced metabolic and functional benefits in overweight or obese non-diabetic participants.
2. Trial design and endpoints
In a randomized, double-blind design, the new arm will administer icovamenib 100 mg QD for 12 weeks alongside low-dose semaglutide for 24 weeks versus low-dose semaglutide alone; enrollment opens in Q3 with primary efficacy assessed at Week 24 on body weight, composition and physical function.
3. Preclinical findings and next steps
Preclinical data demonstrated synergistic fat loss, lean mass preservation and improved glycemic control in diabetic rat models with the combination, supporting its clinical evaluation and forthcoming late-breaking preclinical presentation at the 86th ADA Scientific Sessions.
